Archives for April 25, 2024

← 2024

AstraZeneca’s Lynparza to remain dominant in PARP inhibitors market with $4 billion in sales by 2027

25-Apr-2024

By Isabel Cameron

Back in 2014, AstraZeneca and Merck were the first to receive FDA approval for their PARP inhibitor Lynparza (olaparib) for use in breast cancer gene (BRCA)-mutated metastatic ovarian cancer patients.

University of Dundee spin-out bags £4m to develop active biologic drugs

25-Apr-2024

By Isabel Cameron

UK-based biotech Glen Clova Scientific has raised £4 million in seed financing to develop a pipeline of a new generation of active biologic drugs.

Inizio Engage: Elevating healthcare product launches through smart data

25-Apr-2024

By Isabel Cameron

A recent Deloitte report revealed that 36% of healthcare product launches fell short of achieving 80% of their sales targets within the first two years.